Marrakech, Pullman Palmeraie Resort
COURSES AND SEMINARS
Welcome to the EASO Course on Lights and Shadows in the Management of Prostate Cancer.
As you can see from the programme, we have an array of experts, both from Arab and European countries, who will discuss many timely topics in the prostate cancer field. The programme has taken into account the progress made in surgery, radiation oncology, and medical oncology and should give enough time for everyone to discuss the applicability of recent advances. We will have as special feature the possibility of case presentations throughout the meeting which will be presented by participants, with the aim of facilitating as much as possible interaction and discussion between audience and faculty.
While the School has done its best to invite a very dedicated Faculty, the success of this course will be made by you, by your questions and your participation. We look forward to the interaction with all of you.
Antonio Alcaraz and Karim Touijer
Euro-Arab School of Oncology (EASO)
Via Turati, 29 - 20121 Milan, Italy
Ph: +39 02 85464523
Fax: +39 02 85464545
All participants will be issued a certificate of attendance at the end of the course upon completion of the evaluation form.
The official language of the course will be English and fluency in English is necessary for admission.
No simultaneous translation will be provided.
The badge is the only official evidence of registration and should be worn at all times during the course. Loss of badge means loss of registration.
The organisers bear no responsibility for untoward events in connection with, before, during and after the course. Participants are strongly advised to take out their own personal and travel insurance coverage.
SHARING PROGRESS IN CANCER CARE
Sharing Progress in Cancer Care programme (SPCC) is a pioneering partnership between the European School of Oncology (ESO) and some of the world’s leading pharmaceuticals companies.
This course is organized through an unrestricted grant provided by Sanofi Oncology, sustaining member of the SPCC programme.
H. Ahmed, University College London Hospital, UK
A. Alcaraz, Hospital Clinic, Barcelona, ES
M. Al Otaibi, King Faisal Specialist Hospital and Research Center, Riyadh, KSA
K. Atallah, St Augustin Medical Center, Tunis, TN
A. Bahl, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
N. Benchakroun, Centre Mohamed VI contre le Cancer, Casablanca, MA
A. Bossi, Institut Gustave Roussy, Villejuif, FR
K. Bouzid, Centre Pierre et Marie Curie d'Alger, DZ
A. Briganti, San Raffaele Hospital, Milan, Italy
G. Conti, S. Anna Hospital, Como, IT
K. Fizazi, Institut Gustave Roussy, Villejuif, FR
F. Geara, American University of Beirut, LB
W. Hassen, John Hopkins University/Tawam Hospital, Al-Ain, UAE
A. Joual, Societé Marocaine d’Urologie, Casablanca, MA
T. Karmouni, Hopital Avicenne, Rabat, MA
N. Mottet Auselo, Centre Hospitalier Universitaire Saint-Etienne, FR
J. Romero, Hospital Universitario 12 de Octubre, Madrid, ES
A. Shamseddine, American University of Beirut, LB
B. Tombal, Cliniques Universitaires Saint-Luc, Brussels, BE
K. Touijer, Memorial Sloan Kettering Cancer Centre, New York, US/MA
R. Valdagni, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
| 25 October|
|LOW and INTERMEDIATE RISK DISEASE|
Chairs: A. Alcaraz, ES - A. Joual, MA
|09:00||Imaging in prostate cancer|
T. Karmouni, MA
|09:15||Risk stratification schemas and predictive models in prostate cancer|
K. Touijer, US/MA
|09:30||Clinical cases presentation and discussion in small groups|
- A1. Low risk patient
- A2. Intermediate risk
- A3. Frail low risk patient
|10:30||Interactive clinical cases discussion in plenary session (panel A1, A2, A3)|
Prayer and lunch break
|HIGH RISK DISEASE |
Chairs: G. Conti, IT - F. Geara, LB
Adjuvant versus salvage radiation therapy: when and how ?
Clinical cases presentation and discussion in small groups
|16:30||Interactive clinical cases discussion in plenary session (panel B1, B2, B3)|
Role of androgen deprivation therapy (ADT) in prostate cancer (with radiation therapy/with surgery)
| 26 October|
|RECURRENT DISEASE AND SALVAGE TREATMENTS|
Chairs: A. Bossi, FR - M. Alotaibi, KSA
Salvage treatments for radiation therapy failures
|09:00||Clinical cases presentation and discussion in small groups|
- C1. Focus on diagnostic problems – choline CT-PET for rising PSA after local therapy ?
- C2. Focus on role of surgery
- C3. Focus on role of androgen deprivation therapy (ADT)
|11:00||Interactive clinical cases discussion in plenary session (panel C1, C2, C3)|
Measuring side effects of treatment with validated instruments
Management of urinary dysfunction
|12:10||Management of erectile dysfunction|
J. Romero, ES
|METASTATIC DISEASE |
Chairs: K. Touijer, MA/US - K. Bouzid, DZ
Role of local control
|15:00||Clinical cases presentation and discussion in small groups|
- D1. First diagnosis M+ patient
- D2. PSA progression during HT without met (non-metastatic castration-resistant prostate cancer)
- D3. Patient with metastatic castration-resistant prostate cancer
|16:00||Coffee break |
Interactive clinical cases discussion in plenary session (panel D1, D2, D3)
|17:30||New frontiers for castration-resistant prostate cancer|
A. Bahl, UK